Scinai Immunotherapeutics
SCNI
3 hedge funds and large institutions have $118K invested in Scinai Immunotherapeutics in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
23% more capital inflows, than outflows
Capital inflows: $3.69K | Capital outflows: $3K
0% more funds holding
Funds holding: 3 → 3 (0)
0% more ownership
Funds ownership: 0.18% → 0.18% (+0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$3.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tower Research Capital (TRC)
New York
|
-$3K |
SCNI Hedge Fund Activity: Q2 2016 in Review
3 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2016, worth a combined $118K — down 3.3% from $122K a quarter earlier.
Fund positioning in SCNI was balanced in Q2 2016: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $3.69K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $3K sold.
- 3 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $118K of Scinai Immunotherapeutics stock for Q2 2016, down 3.3% quarter-over-quarter.
- 1 fund opened new Scinai Immunotherapeutics positions in Q2 2016 and 1 closed out, a net change of 0 holders.
- The largest Scinai Immunotherapeutics buyer in Q2 2016 was UBS Group, an estimated $3.69K added.
- The largest Scinai Immunotherapeutics seller in Q2 2016 was Tower Research Capital (TRC), an estimated $3K sold.
Based on aggregated 13F filings for Q2 2016.